glp-1 drug delivery devices Semaglutide vs. Other Receptor Agonists GLP-1 Medications Show Promise as

Endocrinology (2015) 156(10):355969

Beyond genetic variability, differences in metabolic phenotype may significantly influence treatment response

Study found that increasing endogenous and exogenous intestinal SCFAs can stimulate intestinal endocrine cells to secrete GLP-1 and PYY by binding to GPR41 and GPR43 (Tian et al., 2024)

6,18,19 Similar to sitagliptin, saxagliptin is excreted by the kidneys, but it also undergoes hepatic metabolism

Philip Pape: 4:41 The most intriguing of those is the ability to stimulate GLP-1, which is the same hormone targeted by the weight loss medications like Gozembek and Manjaro

PMID 22892942